Form 4: Decheng Capital Funds Reduce BeyondSpring Stake

Decheng Capital funds and affiliates, including Director Xiangmin Cui, reported sales of BeyondSpring Inc. ordinary shares totaling 4,109 shares over three days in late August 2025.

Summary

• Decheng Capital China Life Sciences USD Fund III, L.P., a 10% owner and affiliated with a director, sold a total of 4,109 ordinary shares of BeyondSpring Inc. (BYSI) across three transactions.
• The sales occurred on August 26, 2025 (2,000 shares at a weighted average price of $1.79), August 27, 2025 (1,300 shares at a weighted average price of $1.78), and August 28, 2025 (809 shares at a weighted average price of $1.81).
• These transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.
• Following these transactions, Decheng Capital China Life Sciences USD Fund III, L.P. beneficially owns 1,909,625 ordinary shares.
• Other affiliated entities, Decheng Capital China Life Sciences USD Fund II, L.P. and Decheng Capital Global Healthcare Fund (Master), LP, continue to beneficially own 1,617,409 and 891,734 ordinary shares, respectively.
• The reporting persons, including Decheng Capital Management III (Cayman), LLC, Decheng Capital China Life Sciences USD Fund II, L.P., Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC, and Xiangmin Cui, are all identified as Directors and 10% Owners of BeyondSpring Inc.

Sentiment

Score: 3

Explanation: The sentiment is negative due to insider selling by a significant shareholder and director-affiliated entity, which typically signals reduced confidence or a belief that the stock's upside is limited, despite the transactions being part of a 10b5-1 plan.

Negatives

• A significant shareholder and director-affiliated entity, Decheng Capital, has reduced its stake in BeyondSpring Inc. by selling 4,109 ordinary shares.
• Insider selling, even under a 10b5-1 plan, can be interpreted by the market as a signal of reduced confidence in the company's near-term prospects or valuation by those with intimate knowledge.

Risks

• The sale of shares by a major institutional investor and director-affiliated entity could lead to negative market sentiment and downward pressure on the stock price.
• A reduction in ownership by a significant shareholder might signal a perceived lack of future growth potential or increased risk by the insider.

Future Outlook

NA

Industry Context

Insider transactions, particularly sales by significant shareholders or directors, are closely watched in the biotechnology and pharmaceutical sectors as they can reflect internal perspectives on clinical trial progress, regulatory approvals, or commercialization prospects, which are critical drivers of value in the industry.

Related Party Transactions

• The reported sales of ordinary shares by Decheng Capital China Life Sciences USD Fund III, L.P. are considered related party transactions, as Decheng Capital entities are 10% owners and affiliated with a director (Xiangmin Cui) of BeyondSpring Inc.

Stakeholder Impact

• Shareholders may perceive the insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Potential investors might view the reduction in stake by a major institutional holder as a red flag, influencing their investment decisions.

Key Dates

Recommendation

The insider selling by a significant institutional investor and director-affiliated entity, Decheng Capital, suggests a potential lack of confidence in BeyondSpring Inc.'s near-term prospects or valuation. While these sales are under a 10b5-1 plan, the market often interprets such actions as a negative signal, warranting a 'sell' recommendation for investors to consider reducing their exposure or avoiding the stock.

Keywords

BeyondSpring Inc., BYSI, Decheng Capital, Insider Selling, Form 4, Share Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals, Director Transaction